ArticleInternational ophthalmology2025
Real-world outcomes of selective laser trabeculoplasty in a tertiary referral glaucoma service.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The effect of selective laser trabeculoplasty on the intraocular pressure of the contralateral eye - a systematic review and meta-analysis.Eye (London, England) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSelective laser trabeculoplasty (SLT) is an effective treatment option in open-angle glaucoma (OAG) and ocular hypertension (OHT). The purpose of this study was to evaluate the real-world treatment outcomes of SLT in a tertiary referral glaucoma service.
methodsWe reviewed the medical records of consecutive patients who had undergone SLT in the glaucoma service at the Royal Victoria Eye and Ear Hospital, Dublin. All patients in this study were using topical IOP-lowering medications prior to SLT. The primary outcome measure was the mean change in intraocular pressure (IOP) at 6 to 8 weeks following the procedure.
results71 eyes of 44 patients were included in this study. There was a mean reduction in IOP of 4.0 mmHg (SD 3.6), from 19.1 mmHg (SD 3.6) at baseline to 15.1 mmHg (SD 4.0) at 6 to 8 weeks post-SLT (p < 0.001). The diagnosis was primary open-angle glaucoma (POAG) in 69.0% of eyes, pseudoexfoliation glaucoma (PXFG) in 5.6%, pigment dispersion glaucoma (PDG) in 2.8%, normal tension glaucoma (NTG) in 5.6%, ocular hypertension (OHT) in 15.5%, and pseudoexfoliation OHT in 1.4%. 100% of eyes were on topical IOP-lowering medication (mean number of agents 2.7). In addition, 8.5% had one previous SLT procedure. No immediate (< 1 h) post-SLT IOP spikes occurred in this study. Pearson correlation analysis revealed a moderate correlation (r = -0.4021, p < 0.001) between higher baseline IOP and greater IOP reduction.
conclusionSLT is an effective IOP-lowering treatment in open-angle glaucoma and ocular hypertension in a real-world setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.